MAPK7 and breast cancer: ERK5 activation results in significant decreased migration and invasion of both Hs578T and MDA-MB-231 breast cancer cells, whereas knockdown of ERK5 increases cell migratory and invasive capacities and Vimentin expression, indicating ERK5 as a negative regulator of EMT in these breast cancer cells [30].